Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD +1.53%14 Owner Earnings per Share (TTM) is 3.38 as of Dec. 2025, which is 93% below its 10-year median of 47.13. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 476 Drug Manufacturers companies, Galderma Group AG ranks worse than 76.05% on this metric.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Galderma Group AG's Owner Earnings per Share (TTM) ended in Dec. 2025 was CHF3.38. It's Price-to-Owner-Earnings ratio for today is 51.04.
The historical rank and industry rank for Galderma Group AG's Owner Earnings per Share (TTM) or its related term are showing as below:
XSWX:GALD'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 42.09 Med: 47.13 Max: 53.18
Current: 51.1
XSWX:GALD's Price-to-Owner-Earnings is ranked worse than 76.05% of 476
companies
in the Drug Manufacturers industry
Industry Median: 23.88
vs XSWX:GALD: 51.10
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Galderma Group AG Owner Earnings per Share (TTM) Related Terms
Galderma Group AG Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG Owner Earnings per Share (TTM) Chart
XSWX:GALD vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Price-to-Owner-Earnings vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
1. Start with "Net Income" from income statement. Galderma Group AG's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was CHF489 Mil.
3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income.
Galderma Group AG's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was CHF21 Mil.
4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = CHF121 Mil
It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.
The following shows how to get maintenance capital expenditure.
First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.
Galderma Group AG's 5-Year Average Maintenance Capital Expenditure = CHF121 Mil
5. "Change In Working Capital" is from cashflow statement. Galderma Group AG's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was CHF155 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Owner Earnings per Share (TTM) of 3.38 mean?
Galderma Group AG (XSWX:GALD) has a Owner Earnings per Share (TTM) of 3.38 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Galderma Group AG. This is 93% below median its historical median of 47.13. Over the past decade, Galderma Group AG's Owner Earnings per Share (TTM) has ranged from 42.09 to 53.18. According to the industry distribution chart, Galderma Group AG ranks #362 out of 476 companies in the Drug Manufacturers industry, placing it in the top 76.1%.
Is Galderma Group AG's Owner Earnings per Share (TTM) too high?
Galderma Group AG's current Owner Earnings per Share (TTM) of 3.38 is 93% below median its 10-year median of 47.13. Over the past 10 years, this metric has ranged from a low of 42.09 to a high of 53.18. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.88. Galderma Group AG's value of 3.38 is 85.8% below this industry median. Based on the distribution chart, Galderma Group AG ranks #362 out of 476 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #362 out of 476 companies for Owner Earnings per Share (TTM). This places Galderma Group AG in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.88. Galderma Group AG's value of 3.38 is 85.8% below this benchmark. Historically, Galderma Group AG's own Owner Earnings per Share (TTM) has ranged from 42.09 to 53.18 over the past decade. While the company's 10-year median is 47.13 vs. the industry median of 23.88, Galderma Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.88, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Owner Earnings per Share (TTM) of 3.38 is 85.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Galderma Group AG. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Owner Earnings per Share (TTM) is 3.38, which is 93% below median its own 10-year median of 47.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Owner Earnings per Share (TTM) of 3.38. The current Owner Earnings per Share (TTM) is 3.38, which is 93% below median its 10-year median of 47.13 and 85.8% below the Drug Manufacturers industry median of 23.88. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Owner Earnings per Share (TTM) is 3.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score
Get the complete analysis for XSWX:GALD
Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
